(S)-Phenylpiracetam
Based on 1 Customer Validation
(S)-Phenylpiracetam ((S)-Carphedon; (S)-Fonturacetam; (S)-MRZ 9547) is an orally active and selective dopamine transporter inhibitor, with Ki = 56 μM. (S)-Phenylpiracetam is an isomer of (R)-Phenylpiracetam (HY-14840A). (S)-Phenylpiracetam reduces body weight and fat mass gain, decreases plasma leptin and blood glucose levels, and improves glucose tolerance in obese model animals. (S)-Phenylpiracetam can be used for obesity-related research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 949925-08-0
- Formel: C12H14N2O2
- Molecular Weight:218.25
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Beschreibung
In Vitro
(S)-Phenylpiracetam competitively inhibits [3H]WIN 35,428 binding to DAT in rat brain striatal membranes with a Ki of 56 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
(S)-Phenylpiracetam (50 mg/kg; p.o.; daily; 8 weeks) reduces mean body weight by 26%, decreases fat mass by 45%, lowers hyperleptinemia by 61%, improves glucose tolerance, and reduces hyperglycemia in WD-fed mice without altering plasma insulin concentrations[1].
(S)-Phenylpiracetam (50-100 mg/kg; p.o.; single administration) at a dose of 100 mg/kg results in significantly greater travel distance and speed than the R-Phenylpiracetam (HY-14840A) treatment group[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Zucker rats (HsdOla:ZUCKER)-Leprfa (male, obese, 7 weeks old, 130-200 g)[1]
-
Dosage:50 mg/kg
-
Administration:p.o.; daily; 12 weeks
-
Result:Reduced body mass increase by 16% after 12 weeks.
Significantly reduced fat mass increase from the 3rd week through the 12th week.
Showed a tendency to consume less food than obese control rats.
Significantly decreased fed-state blood glucose concentration compared to the obese control.
Did not influence fasted-state blood glucose concentration.
Showed a tendency to improve glucose tolerance.
Did not change insulin concentration in obese rats.\nDid not affect moved distance or velocity in obese rats.
Moved distance was 3294 cm and velocity 3.7 cm/s in treated obese rats, compared to 3645 cm and 4.1 cm/s in obese controls, and 4915 cm and 5.5 cm/s in lean controls.
-
Animal Model:C57BL/6N mice (male, 7 weeks old, 21-25 g)[1]
-
Dosage:50 mg/kg
-
Administration:p.o.; daily; 8 weeks
-
Result:Significantly decreased body weight gain starting from week 6; average body weight was 26% lower than WD control at week 8.
Decreased fat mass significantly by 45% after 8 weeks.
Significantly reduced WD-induced hyperglycemia in the fed and fasted state.
Significantly improved glucose tolerance.
Glucose AUC was significantly lower than in WD-fed mice.
Reduced hyperleptinemia by 61% after 8 weeks.
Did not change plasma insulin concentration.\nDid not affect moved distance or velocity in WD-fed mice.
Moved distance was 1607 cm and velocity 6.7 cm/s in treated WD mice, compared to 1700 cm and 7.1 cm/s in WD controls, and 1812 cm and 7.6 cm/s in normal diet mice.
-
Animal Model:SW mice (male, 16 weeks old, 40-50 g)[1]
-
Dosage:50 and 100 mg/kg
-
Administration:p.o.; single administration
-
Result:Did not increase locomotor activity in mice in the open-field test at 50 mg/kg, while at 100 mg/kg it showed significantly higher moved distance and velocity than the R-Phenylpiracetam-treated group.
Chemical Information
-
CAS. Nr. 949925-08-0
-
Appearance Solid
-
Molecular Weight 218.25
-
Formel C12H14N2O2
-
SMILES
O=C(N)CN1C(C[C@@H](C2=CC=CC=C2)C1)=O
-
Synonyms
(S)-Carphedon; (S)-Fonturacetam; (S)-MRZ 9547
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 100 mg/mL (458.19 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Reinheit & Dokumentation
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.5819 mL | 22.9095 mL | 45.8190 mL | 114.5475 mL |
| 5 mM | 0.9164 mL | 4.5819 mL | 9.1638 mL | 22.9095 mL | |
| 10 mM | 0.4582 mL | 2.2910 mL | 4.5819 mL | 11.4548 mL | |
| 15 mM | 0.3055 mL | 1.5273 mL | 3.0546 mL | 7.6365 mL | |
| 20 mM | 0.2291 mL | 1.1455 mL | 2.2910 mL | 5.7274 mL | |
| 25 mM | 0.1833 mL | 0.9164 mL | 1.8328 mL | 4.5819 mL | |
| 30 mM | 0.1527 mL | 0.7637 mL | 1.5273 mL | 3.8183 mL | |
| 40 mM | 0.1145 mL | 0.5727 mL | 1.1455 mL | 2.8637 mL | |
| 50 mM | 0.0916 mL | 0.4582 mL | 0.9164 mL | 2.2910 mL | |
| 60 mM | 0.0764 mL | 0.3818 mL | 0.7637 mL | 1.9091 mL | |
| 80 mM | 0.0573 mL | 0.2864 mL | 0.5727 mL | 1.4318 mL | |
| 100 mM | 0.0458 mL | 0.2291 mL | 0.4582 mL | 1.1455 mL |
(S)-Phenylpiracetam Related Classifications
HY-14910 Related Classifications
Powered by Bioz
Keywords
- (S)-Phenylpiracetam
- 949925-08-0
- (S)-Carphedon
- (S)-Fonturacetam
- (S)-MRZ 9547
- Dopamine Transporter
- Drug Isomer
- obesity
- fat mass
- dopamine reuptake inhibitor
- glucose tolerance
- hyperleptinemia
- body weight gain
- dopamine transporter binding site
- locomotor activity
- obese Zucker rats
- Western diet-fed mice
- Inhibitor
- inhibitor
- inhibit